EA201101300A1 - Способ или система на основе биомаркеров, предназначенная для мониторинга лечения - Google Patents

Способ или система на основе биомаркеров, предназначенная для мониторинга лечения

Info

Publication number
EA201101300A1
EA201101300A1 EA201101300A EA201101300A EA201101300A1 EA 201101300 A1 EA201101300 A1 EA 201101300A1 EA 201101300 A EA201101300 A EA 201101300A EA 201101300 A EA201101300 A EA 201101300A EA 201101300 A1 EA201101300 A1 EA 201101300A1
Authority
EA
Eurasian Patent Office
Prior art keywords
biomarkers
intended
system based
monitoring treatment
monitoring
Prior art date
Application number
EA201101300A
Other languages
English (en)
Inventor
Токузо Арао
Канае Кудо
Казухико Накагава
Казуто Нишио
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201101300(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201101300A1 publication Critical patent/EA201101300A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описаны биомаркеры для мониторинга активности такого соединения, как 3--[1-(4-(-((4-метилпиперазин-1-ил)мeтилкapбoнил)-N-метиламино)анилино)-1-фенилметилен]-6-метоксикарбонил-2-индолинон или его фармацевтически приемлемая соль, предпочтительно моноэтансульфонат, при применении индивидуально или необязательно в сочетании с другими фармацевтическими действующими веществами и/или другими методами лечения, такими, например, как лучевая терапия.
EA201101300A 2009-03-12 2010-03-11 Способ или система на основе биомаркеров, предназначенная для мониторинга лечения EA201101300A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09154964 2009-03-12
PCT/EP2010/053063 WO2010103058A1 (en) 2009-03-12 2010-03-11 Method or system using biomarkers for the monitoring of a treatment

Publications (1)

Publication Number Publication Date
EA201101300A1 true EA201101300A1 (ru) 2012-04-30

Family

ID=42129920

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101300A EA201101300A1 (ru) 2009-03-12 2010-03-11 Способ или система на основе биомаркеров, предназначенная для мониторинга лечения

Country Status (24)

Country Link
US (1) US8802384B2 (ru)
EP (1) EP2406628A1 (ru)
JP (1) JP5667581B2 (ru)
KR (1) KR20110137307A (ru)
CN (1) CN102334030A (ru)
AR (1) AR076113A1 (ru)
AU (1) AU2010223256B2 (ru)
BR (1) BRPI1011688A2 (ru)
CA (1) CA2755055A1 (ru)
CL (1) CL2011002260A1 (ru)
CO (1) CO6430497A2 (ru)
EA (1) EA201101300A1 (ru)
EC (1) ECSP11011323A (ru)
IL (1) IL214747A0 (ru)
MA (1) MA33120B1 (ru)
MX (1) MX2011009482A (ru)
NZ (1) NZ594843A (ru)
PE (1) PE20120592A1 (ru)
SG (1) SG174324A1 (ru)
TN (1) TN2011000457A1 (ru)
TW (1) TW201100802A (ru)
UA (1) UA107789C2 (ru)
UY (1) UY32482A (ru)
WO (1) WO2010103058A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029996B1 (ru) 2008-06-06 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Капсулярная лекарственная форма, содержащая суспензионную композицию производного индолинона
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015017728A1 (en) 2013-07-31 2015-02-05 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US11397178B2 (en) 2016-10-28 2022-07-26 Cedars-Sinai Medical Center Method of predicting progression of idiopathic pulmonary fibrosis and monitoring of therapeutic efficacy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75054C2 (ru) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Замещенные в положении 6 индолиноны, их получение и их применение как лекарственного средства
US6762180B1 (en) * 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
EP1571225A1 (en) 2004-03-02 2005-09-07 PrimaGen Holding B.V. Diagnosis of a disease and monitoring of therapy using the AC133 gene
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2008103B1 (en) 2006-04-18 2010-07-28 Wellstat Biologics Corporation Detection of circulating endothelial cells
EP1870400A1 (en) 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Salts and crystalline salt forms of an 2-indolinone derivative
MX2009002471A (es) * 2006-09-07 2009-03-20 Astrazeneca Ab Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora.
JP2010524003A (ja) 2007-04-13 2010-07-15 ブリストル−マイヤーズ スクイブ カンパニー 血管内皮増殖因子受容体−２モジュレーターに対する感受性を決定するためのバイオマーカーおよび方法
US20100184049A1 (en) 2007-04-27 2010-07-22 Steve Goodison Glycoprotein Profiling of Bladder Cancer

Also Published As

Publication number Publication date
US8802384B2 (en) 2014-08-12
PE20120592A1 (es) 2012-06-09
NZ594843A (en) 2014-03-28
JP2012520446A (ja) 2012-09-06
UY32482A (es) 2010-10-29
CO6430497A2 (es) 2012-04-30
SG174324A1 (en) 2011-10-28
EP2406628A1 (en) 2012-01-18
TN2011000457A1 (en) 2013-03-27
ECSP11011323A (es) 2011-10-31
JP5667581B2 (ja) 2015-02-12
MX2011009482A (es) 2011-09-27
AU2010223256A1 (en) 2011-09-15
CN102334030A (zh) 2012-01-25
MA33120B1 (fr) 2012-03-01
BRPI1011688A2 (pt) 2016-03-22
AR076113A1 (es) 2011-05-18
TW201100802A (en) 2011-01-01
WO2010103058A1 (en) 2010-09-16
IL214747A0 (en) 2011-11-30
US20100233705A1 (en) 2010-09-16
UA107789C2 (en) 2015-02-25
CA2755055A1 (en) 2010-09-16
AU2010223256B2 (en) 2014-08-21
KR20110137307A (ko) 2011-12-22
CL2011002260A1 (es) 2012-03-23

Similar Documents

Publication Publication Date Title
EA201101300A1 (ru) Способ или система на основе биомаркеров, предназначенная для мониторинга лечения
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
EA201100335A1 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
EA201200793A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
UA98629C2 (ru) Соединения и способ модуляции киназ
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
WO2011127070A3 (en) IRE-1α INHIBITORS
MY175979A (en) Certain chemical entities, compositions and methods
EA201270803A1 (ru) Тиоацетатные соединения, композиции на их основе и способы их применения
TN2011000239A1 (en) Hsp90 inhibitor combinations
CO6321253A2 (es) Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4- amino-5- fluoro-3-[5-(4-metil-piperazin-1-il)1h-bencimidazol-2-il]-quinolin-2(1h)-ona
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
UA97795C2 (ru) Дейтерированные производные катехоламина и медикаменты, которые содержат упомянутые соединения
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201000428A1 (ru) Оксадиазол- и оксазолзамещенные производные бензимидазола и индола как ингибиторы dgat1
EA201492184A1 (ru) Способы лечения метаболического синдрома путем модулирования белка теплового шока (hsp) 90-бета
EA201370008A1 (ru) Лечение когнитивных нарушений
WO2008052189A3 (en) Micropore delivery of active substances
WO2010034015A3 (en) Modulating the alternative complement pathway
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
CL2010001362A1 (es) Forma de dosificacion farmaceutica para la liberacion inmediata de la sustancia activa 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metileno]-6-metoxicarbonil-2-indolinona-monoetanosulfonato; y su uso para el tratamiento y/o prevencion de enfermedades oncologicas e inmunologicas, entre otras.
ATE439347T1 (de) 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
NO20072890L (no) Behandling av mastitt
WO2011163512A3 (en) Cancer therapy
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування